0.54 (-%)
As of Nov 22, 2024
Source:
We are a clinical stage microbiome product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as cystic fibrosis, or CF, atopic dermatitis, or AD, inflammatory bowel disease, or IBD, primary sclerosing cholangitis, or PSC and colorectal cancer, or CRC. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells.
Country | United States |
Headquarters | ness ziona |
Phone Number | (972) 72 394 2377 |
Industry | manufacturing |
CEO | Jonathan Solomon |
Website | www.clinicaltrials.gov |